PURPOSE: Cardiovascular disease (CVD) is the leading cause of death in adults in the United States, yet the benefits of genetic testing are not universally accepted. METHODS: We developed the "HeartCare" panel of genes associated with CVD, evaluating high-penetrance Mendelian conditions, coronary artery disease (CAD) polygenic risk, LPA gene polymorphisms, and specific pharmacogenetic (PGx) variants. We enrolled 709 individuals from cardiology clinics at Baylor College of Medicine, and samples were analyzed in a CAP/CLIA-certified laboratory. Results were returned to the ordering physician and uploaded to the electronic medical record. RESULTS: Notably, 32% of patients had a genetic finding with clinical management implications, even after excluding PGx results, including 9% who were molecularly diagnosed with a Mendelian condition. Among surveyed physicians, 84% reported medical management changes based on these results, including specialist referrals, cardiac tests, and medication changes. LPA polymorphisms and high polygenic risk of CAD were found in 20% and 9% of patients, respectively, leading to diet, lifestyle, and other changes. Warfarin and simvastatin pharmacogenetic variants were present in roughly half of the cohort. CONCLUSION: Our results support the use of genetic information in routine cardiovascular health management and provide a roadmap for accompanying research.
PURPOSE: Cardiovascular disease (CVD) is the leading cause of death in adults in the United States, yet the benefits of genetic testing are not universally accepted. METHODS: We developed the "HeartCare" panel of genes associated with CVD, evaluating high-penetrance Mendelian conditions, coronary artery disease (CAD) polygenic risk, LPA gene polymorphisms, and specific pharmacogenetic (PGx) variants. We enrolled 709 individuals from cardiology clinics at Baylor College of Medicine, and samples were analyzed in a CAP/CLIA-certified laboratory. Results were returned to the ordering physician and uploaded to the electronic medical record. RESULTS: Notably, 32% of patients had a genetic finding with clinical management implications, even after excluding PGx results, including 9% who were molecularly diagnosed with a Mendelian condition. Among surveyed physicians, 84% reported medical management changes based on these results, including specialist referrals, cardiac tests, and medication changes. LPA polymorphisms and high polygenic risk of CAD were found in 20% and 9% of patients, respectively, leading to diet, lifestyle, and other changes. Warfarin and simvastatin pharmacogenetic variants were present in roughly half of the cohort. CONCLUSION: Our results support the use of genetic information in routine cardiovascular health management and provide a roadmap for accompanying research.
Authors: Nadine Norton; Duanxiang Li; Mark J Rieder; Jill D Siegfried; Evadnie Rampersaud; Stephan Züchner; Steve Mangos; Jorge Gonzalez-Quintana; Libin Wang; Sean McGee; Jochen Reiser; Eden Martin; Deborah A Nickerson; Ray E Hershberger Journal: Am J Hum Genet Date: 2011-02-25 Impact factor: 11.025
Authors: L B Ramsey; S G Johnson; K E Caudle; C E Haidar; D Voora; R A Wilke; W D Maxwell; H L McLeod; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi Journal: Clin Pharmacol Ther Date: 2014-06-11 Impact factor: 6.875
Authors: Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall Journal: N Engl J Med Date: 2009-12-24 Impact factor: 91.245
Authors: Joshua L Deignan; Wendy K Chung; Hutton M Kearney; Kristin G Monaghan; Catherine W Rehder; Elizabeth C Chao Journal: Genet Med Date: 2019-04-24 Impact factor: 8.822
Authors: Theodore Chiang; Xiuping Liu; Tsung-Jung Wu; Jianhong Hu; Fritz J Sedlazeck; Simon White; Daniel Schaid; Mariza de Andrade; Gail P Jarvik; David Crosslin; Ian Stanaway; David S Carrell; John J Connolly; Hakon Hakonarson; Emily E Groopman; Ali G Gharavi; Alexander Fedotov; Weimin Bi; Magalie S Leduc; David R Murdock; Yunyun Jiang; Linyan Meng; Christine M Eng; Shu Wen; Yaping Yang; Donna M Muzny; Eric Boerwinkle; William Salerno; Eric Venner; Richard A Gibbs Journal: Genet Med Date: 2019-03-20 Impact factor: 8.822
Authors: S E Humphries; J A Cooper; M Seed; N Capps; P N Durrington; B Jones; I F W McDowell; H Soran; H A W Neil Journal: Atherosclerosis Date: 2018-05-01 Impact factor: 5.162
Authors: Amit V Khera; Mark Chaffin; Krishna G Aragam; Mary E Haas; Carolina Roselli; Seung Hoan Choi; Pradeep Natarajan; Eric S Lander; Steven A Lubitz; Patrick T Ellinor; Sekar Kathiresan Journal: Nat Genet Date: 2018-08-13 Impact factor: 38.330
Authors: Emily J Hill; Laurie A Robak; Rami Al-Ouran; Jennifer Deger; Jamie C Fong; Paul Jerrod Vandeventer; Emily Schulman; Sindhu Rao; Hiba Saade; Joseph M Savitt; Rainer von Coelln; Neeja Desai; Harshavardhan Doddapaneni; Sejal Salvi; Shannon Dugan-Perez; Donna M Muzny; Amy L McGuire; Zhandong Liu; Richard A Gibbs; Chad Shaw; Joseph Jankovic; Lisa M Shulman; Joshua M Shulman Journal: Neurol Genet Date: 2022-06-09
Authors: Chayakrit Krittanawong; Kipp W Johnson; Edward Choi; Scott Kaplin; Eric Venner; Mullai Murugan; Zhen Wang; Benjamin S Glicksberg; Christopher I Amos; Michael C Schatz; W H Wilson Tang Journal: Life (Basel) Date: 2022-02-14
Authors: Alana C Cecchi; Madeline Drake; Chrisanne Campos; Jake Howitt; Jonathan Medina; Scott M Damrauer; Sherene Shalhub; Dianna M Milewicz Journal: Semin Vasc Surg Date: 2022-02-25 Impact factor: 1.222